Secondary endpoints aside, Alcobra heralds PhII 'success'; Chiasma hunts for new HQ;

@FierceBiotech: FierceBiotech Radio with Express Scripts' Steve Miller. More | Follow @FierceBiotech

@JohnCFierce: Biopharma's new normal: Constant makeovers leave R&D jobs at permanent risk. Editor's corner | Follow @JohnCFierce

@DamianFierce: Hey @FierceBiotech's podcast is now available on Stitcher. If you know what that means, here you go. | Follow @DamianFierce

> Israel's Alcobra said that its Phase II ADHD study for its drug MDX hit the primary endpoint for safety, but the company raised eyebrows with the added note that secondary cognitive endpoints were not met in the trial. Nevertheless, the biotech called the study, which enrolled 83 adolescents, a success. Release

> The Boston Business Journal reports that Chiasma is looking for a new HQ in Cambridge or Newton, MA. Story

Medical Device News

@FierceMedDev: Exact Sciences signs on Anthem and Aetna to noninvasive colon cancer Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: FDA approves novel blood purifier that treats rare condition in hemodialysis patients. Report | Follow @VarunSaxena2

@EmilyWFierce: Check out FierceBiotech Radio's latest podcast with Express Scripts CMO Steve Miller on iTunes. | Follow @EmilyWFierce

> Veniti raises $17M to complete pivotal venous stent trial aimed at FDA approval. News

> Apple announces open-source data-collection platform for mobile medical apps. Story

> Study: FDA-cleared biomarker can reduce ADHD overdiagnosis. Article

Pharma News

@FiercePharma: Bayer puts cancer-fighting country crooner onstage to promote colonoscopies. FiercePharmaMarketing article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: MS Pharma in Jordan gets $30M development loan to expand its drug manufacturing. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI: GSK sacks 100-plus China workers for misconduct in wake of bribery scandal. Report | Follow @CarlyHFierce

> Activist investor Ackman nabs $3B-plus stake in former takeover partner Valeant. Report

> New Bristol-Myers CEO on tap for $8.7M-plus pay package. Story

> Bharat's $1 rotavirus vax rolls out in India to challenge GSK, Merck. Article

Biotech Research News

> Mouse model for rheumatoid arthritis responds to M-MDSCs. Item

> Salk scientists use new CRISPR tech to chop up HIV. More

> Activating thyroid hormone receptor may rev up metabolism. Story

> UC Berkeley team puts its heart into latest organ-on-a-chip project. Article

> Mayo/Scripps team begins testing a new class of anti-aging drugs. Report

Pharma Manufacturing News

> Sun's buyout of Ranbaxy gets India's approval. Item

> U.S. biotech buying Belgium cell manufacturer for $25M. News

> Hospira recalls more saline as well as drug used during pregnancy. Report

> Patheon strikes again; deal for Agere its second in a week. Story

> Recro picks up Alkermes plant, pain drugs and contract biz. Article

Pharma Asia News

> Boehringer Spiriva patent revoked in Cipla challenge in India. Item

> SK Chemicals gets Korea nod for cell-culture flu vaccine 'SKYCellflu.' Report

> Japan's R-Tech Ueno evaluates options as PhIII candidate Unoprostone fails primary endpoint. More

> Sun and Ranbaxy now a couple as last hurdle cleared for India's top drug company. Story

> Sri Lanka poised to launch mandatory generics-first policy. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.